Biotech co Alector rises after premium-priced $75 mln stock sale

By Reuters News

** Biotech firm Alector's ALEC.O shares up 6.8% at $2.04 before the bell on Fri after $75 mln follow-on priced

** ALEC sells 36.6 mln shares at $2.05, 7.3% above their last sale on Thurs

** Financing includes participation from new and existing investors, including TCGX, BVF Partners, among others, co says

** It intends to use net offering proceeds for general purposes, including R&D, working capital, capex, expenses, potential acquisitions

** Morgan Stanley and BTIG joint bookrunners

** On Oct 5, ALEC's stock ultimately finished session up ~10% at $1.99 after it announced that Genentech, a unit of Swiss drugmaker Roche ROPC.S, will pay up to $1.27 bln to license AL050, ALEC's experimental drug for Parkinson's disease

** South San Francisco, California-based ALEC has ~111.7 mln shares outstanding

** At Thurs close, stock up 30% over the past three months

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.